{"organizations": [], "uuid": "5583b36c79c88ced24ecafe7e8c506ce0f280328", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-agios-outlines-key-2018-priorities/brief-agios-outlines-key-2018-priorities-expanding-clinical-and-research-programs-to-drive-long-term-value-idUSFWN1P30J1", "country": "US", "domain_rank": 408, "title": "BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T14:19:00.000+02:00", "replies_count": 0, "uuid": "5583b36c79c88ced24ecafe7e8c506ce0f280328"}, "author": "", "url": "https://www.reuters.com/article/brief-agios-outlines-key-2018-priorities/brief-agios-outlines-key-2018-priorities-expanding-clinical-and-research-programs-to-drive-long-term-value-idUSFWN1P30J1", "ord_in_thread": 0, "title": "BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "agios", "sentiment": "none"}, {"name": "agios pharmaceuticals inc", "sentiment": "none"}, {"name": "drive long term value reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "agios pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 20 PM / Updated 17 minutes ago BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value Reuters Staff \nJan 8 (Reuters) - Agios Pharmaceuticals Inc: \n* AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE \n* AGIOS PHARMACEUTICALS INC - SEVENTH IND SUBMISSION FOR A DHODH INHIBITOR FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES EXPECTED IN 4Q 2018 \n* AGIOS - 2017 YEAR END CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $568M FUNDS EXPANDED CLINICAL & RESEARCH PROGRAMS THROUGH END OF 3Q 2019 \n* AGIOS PHARMACEUTICALS INC - TWO PIVOTAL TRIALS IN PYRUVATE KINASE DEFICIENCY WITH AG-348, ACTIVATE-T TO INITIATE IN 1Q 2018 AND ACTIVATE IN 2Q 2018 \n* AGIOS PHARMACEUTICALS INC - PHASE 2 PROOF OF CONCEPT TRIAL OF AG-348 IN THALASSEMIA PLANNED FOR 4Q 2018 \n* AGIOS PHARMACEUTICALS INC - MAT2A INHIBITOR AG-270 EXPECTED TO ENTER PHASE 1 DOSE-ESCALATION TRIAL IN MTAP-DELETED TUMORS IN 1Q 2018 Source text for Eikon:  ", "external_links": [], "published": "2018-01-08T14:19:00.000+02:00", "crawled": "2018-01-08T14:40:00.014+02:00", "highlightTitle": ""}